Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$1.36B
-0.9% from 2023
Prescriptions
2.6M
$519.83 per claim
Patients
596K
198,445 prescribers
Total spending, 2024
$1.36B
$2,282.57 per patient
Medicare prescription drug plans paid $1.36B for Breo Ellipta in 2024, for 2,616,366 prescriptions and refills to 595,847 patients (down 0.9% from 2023). The average cost per claim was $519.83.
New York had the highest Medicare cost for Breo Ellipta in 2024: $108.4M for 210,843 claims, followed by Pennsylvania ($93.9M).
Domingo Chardon, pulmonary disease in Ponce, PR, had the highest Medicare cost for Breo Ellipta in 2024: 2,153 claims costing $900K.
Breo Ellipta is made by GSK plc (GSK), listed in the Medicare spending data as Glaxosmithkline.
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Domingo Chardon Ponce, PR | Pulmonary Disease | 2,153 | 484 | $900K |
| Carissa M Cruz Berrios Humacao, PR | Internal Medicine | 2,144 | 610 | $892K |
| Juan C Acevedo-Crespo |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 190,333 | 2,705,064 | 604,884 | $1.43B |
| 2023 | 186,555 | 2,469,859 | 556,496 | $1.37B |
| 2024 | 198,445 | 2,616,366 | 595,847 | $1.36B |
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Pulmonary Disease |
| 1,542 |
| 386 |
| $661K |
| Carlos N Montalvo Bonilla Arecibo, PR | Internal Medicine | 1,437 | 318 | $604K |
| Sergio Bures Katonah, NY | Pulmonary Disease | 701 | 170 | $540K |
| Jorge Sanchez-Masiques Miami, FL | Pulmonary Disease | 1,254 | 237 | $513K |
| Carlos R Alcala Marquez San Juan, PR | Pulmonary Disease | 1,218 | 237 | $506K |
| Gary R Schafer Forest City, NC | Pulmonary Disease | 998 | 177 | $500K |
| Seema Agarwal Bronx, NY | Pulmonary Disease | 642 | 194 | $476K |
| Jason B Karp Lake Success, NY | Pulmonary Disease | 605 | 189 | $470K |
| Shamim A Najeebi Springfield, MA | Hospitalist | 985 | 173 | $459K |
| Jack Hasson Birmingham, AL | Pulmonary Disease | 931 | 179 | $427K |
| Thomas K Chan New York, NY | Pulmonary Disease | 1,025 | 153 | $412K |
| Andres A Redondo Miami, FL | Pulmonary Disease | 1,002 | 217 | $403K |
| Reinaldo Gonzalez Martinez Bayamon, PR | Pulmonary Disease | 939 | 221 | $391K |
| Dima Adl Milwaukee, WI | Pulmonary Disease | 563 | 131 | $388K |
| Melissa D Cohen Mineola, NY | Pulmonary Disease | 519 | 128 | $385K |
| Kaiser Toosy New Haven, CT | Pulmonary Disease | 736 | 160 | $379K |
| Agnieszka Palecki Forked River, NJ | Pulmonary Disease | 526 | 152 | $361K |
| Irina Zolotarevskaya Rego Park, NY | Pulmonary Disease | 866 | 116 | $350K |
| Hyrza M Vazquez Rivera Bayamon, PR | Pulmonary Disease | 829 | 193 | $347K |
| Ganesha Santhyadka Bangor, ME | Pulmonary Disease | 707 | 141 | $346K |
| Allan J Rodrigues New Haven, CT | Pulmonary Disease | 582 | 107 | $335K |
| Moses M Kitakule New Iberia, LA | Internal Medicine | 688 | 146 | $327K |
| Rudolf Khusid Yardley, PA | Pulmonary Disease | 767 | 100 | $317K |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Glaxosmithkline GSK | 2,617,269 | $1.36B |